Title
Category
Credits
Event date
Cost
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
Genitourinary malignancies will account for approximately 20% of newly diagnosed cancers in 2021. Recent research advances in prostate, bladder, and kidney cancers utilizing new biomarkers and imaging tools, radiolabeled therapy, targeted therapy, immunotherapy and antibody-drug conjugates have led to new management approaches associated with significant improvements in patient outcomes.
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
This lecture will provide an overview of the burden and outcomes of COVID-19 among patients living with cancer. We will also review the impact of the pandemic on cancer care delivery, and emerging data regarding vaccination safety and efficacy.
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
Immune Thrombocytopenic Purpura and Thrombotic Thrombocytopenic Purpura are both autoimmune conditions leading to low platelets, though the mechanism by which the platelets are consumed differs.  The lecture will update viewers on new therapies for the treatment of ITP and TTP
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
Wendell Yarbrough, MD, MMHC, FACS, will lecture on multi-disciplinary treatment of head and neck cancer with updates regarding new techniques and treatment standards. This lecture will also give the audience updates on HPV-Associated Head and Neck Cancer with emerging therapeutic vulnerabilities. 
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
This lecture is an interactive presentation and discussion to consider barriers to cancer clinical trial enrollment in North Carolina and potential approaches to address this. Topics will include the importance of patient and provider engagement, education and resources for identifying research opportunities and available trials, barriers and mitigation strategies to address population disparities in trial enrollment, and other issues.
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
Dr. Christopher Dittus from the UNC Lineberger Lymphoma group will describe relevant updates in systemic therapy for rare lymphomas for health care providers throughout the state of North Carolina. Additional topical management considerations or recommendations for this patient population may also be presented.
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
Dr. Benyam Muluneh from the UNC Eshelman School of Pharmacy will discuss relevant topics in cancer pharmacy for North Carolina cancer providers, such as adherence to oral anti-cancer therapies, evolving pharmaceutical practice models (e.g. specialized clinics), toxicity measurement and management, access, and other issues.
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
Dr. James from the UNC Anesthesiology Department in affiliation with UNC Lineberger cancer treatment group, will describe effects of regional and neuraxial perioperative blocks on cancer outcomes. Additional topical management considerations or recommendations for this patient population may also be presented.
  • ACPE Pharmacist
  • ACPE Pharmacy Tech
  • AMA PRA Category 1 Credit
  • ASRT
  • NCPD/CNE
  • Participation
$0.00
Shetal Patel, MD, PhD, from the UNC Lineberger Thoracic Oncology group will describe relevant updates in systemic therapy for lung cancers for health care providers throughout the state of North Carolina. Additional topical management considerations or recommendations for this patient population may also be presented.
  • Participation
$0.00
Describe the types, stages and diagnostic tests available for treating pediatric cancer patients. Discuss the treatment options, management of side effects and emotional needs of pediatric cancer patients and their families.

Pages